Pharma BD Deal Intelligence
A validating exit for Roivant's holding-company model: Sumitomo paid roughly $3 billion for five Vant subsidiaries plus a stake in Roivant itself, ahead of Sumitomo's Latuda loss of exclusivity, though Urovant was taken private again within a year.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ramaswamy: 'They have great cash flow but no meaningful growth engine. We have a great growth engine and no meaningful cash flows' — analysts read this as a…
Completion of the strategic alliance with Roivant Sciences, effective December 27, 2019: ~US$3B (JPY 330B) = US$2.0B for all stock of Sumitovant Biopharma +…
Sumitovant completed acquisition of Myovant Sciences on March 10, 2023 (~$1.7B for shares not already owned); Myovant delisted from the NYSE.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sumitomo Dainippon Pharma acquired Roivant's interests in five 'Vant' subsidiaries — Myovant, Urovant, Enzyvant, Altavant and Spirovant — bundled under a new holding company, Sumitovant Biopharma, plus an equity stake in Roivant itself. Per Sumitomo's completion disclosure, total consideration was approximately US$3 billion (~JPY 330 billion): US$2.0 billion for 100% of Sumitovant Biopharma (the five Vants) and US$1.0 billion for an 11% equity stake in Roivant. The deal also granted Sumitomo options over six additional Roivant biopharma companies and access to Roivant's DrugOme and Digital Innovation technology platforms. Announced October 31, 2019; closed December 27, 2019, with Sumitovant launched as a wholly owned subsidiary led by CEO Myrtle Potter. Sumitomo subsequently consolidated the portfolio: Urovant was taken private (announced November 2020); Sumitovant completed the buy-in of the remaining Myovant shares it did not own on March 10, 2023 (~US$1.7 billion, NYSE delisting); and the U.S. entities were combined into Sumitomo Pharma America effective July 1, 2023.
Assessment window: 5yr post-close.
Sumitovant's portfolio spans high-prevalence women's/men's health (uterine fibroids, endometriosis, advanced prostate cancer, overactive bladder) and ultra-rare pediatric immune, pulmonary hypertension, and cystic fibrosis indications. The lead Vants (Myovant, Urovant) targeted GnRH/beta-3 mechanisms with Phase 3 readouts already in hand at the time of deal close.
The Sumitovant alliance is best understood as a portfolio bet, not a single-indication play. Myovant's relugolix (oral GnRH antagonist) was advancing Phase 3 in uterine fibroids (LIBERTY) and advanced prostate cancer (HERO) against AbbVie/Neurocrine's Orilissa (elagolix, endometriosis) and entrenched leuprolide depot brands (Lupron, Eligard, Trelstar). Urovant's vibegron (beta-3 agonist) had positive Phase 3 EMPOWUR data in overactive bladder, positioning it against Astellas' Myrbetriq plus generic antimuscarinics. Enzyvant carried RVT-802 for congenital athymia (later approved as Rethymic, 2021), Altavant held rodatristat ethyl for pulmonary arterial hypertension (vs. United Therapeutics' tyvaso/Uptravi franchise), and Spirovant pursued AAV gene therapy for cystic fibrosis (vs. Vertex's Trikafta dominance). For Sumitomo Dainippon, the deal was a pre-Latuda-LOE diversification play to replace the schizophrenia revenue cliff in 2023; for Roivant, it monetized late-stage assets while preserving optionality on six additional Vants. Analysts framed the price as full but defensible given relugolix/vibegron Phase 3 reads, and Stifel/Jefferies modeled blockbuster potential for the lead programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) (this deal) | 2019 | $3.0B | — |
| Sumitomo Dainippon Pharma Co., Ltd. / Cynapsus Therapeutics Inc. | 2016 | $624M | 28 |
| Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc. | 2016 | $780M | 24 |
| Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd. | 2021 | $270M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
← Browse all deals · How we score deals
More: 2019 deals · Sumitomo Dainippon Pharma Co., Ltd. deals · Oncology deals